Obsidian Therapeutics to Present Updated Amsoki-cel Data at SITC 2026
Obsidian Therapeutics will present updated Phase 1/2 data for its Amsoki-cel (OBX-115) therapy in advanced melanoma patients at the SITC 2026 Annual Meeting.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.